Introduction to Intermediate Risk Prostate Cancer
Exploring Intermediate Risk Prostate Cancer reveals several interesting facts. MUSC Hollings
Intermediate Risk Prostate Cancer Comprehensive Overview
Join Dr. Art Rastinehad in this enlightening session tailored for patients facing unfavorable Intermediate PCRI's Executive Director, Mark Scholz, MD, compares different treatments for men with Teal stage (
Dr Mack Roach III speaks to ecancer about early results of a phase III randomised controlled trial. The trial investigated androgen ...
Summary & Highlights for Intermediate Risk Prostate Cancer
- Filmed in February 2020 Backed by extensive clinical evidence, the Decipher®
- Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for
- James A. Eastham, MD, FACS, considers how to select candidates for active surveillance in the
- This video will discuss the the success rate and the side effects with Cyberknife and surgery for unfavorable
- In this episode of BackTable Urology, Dr. Aditya Bagrodia discusses radiation therapy for favorable
Stay tuned for more updates related to Intermediate Risk Prostate Cancer.